Turning Point Therapeutics Inc (OQ:TPTX)

Business Focus: Biotechnology & Medical Research

Latest 10 SEC filings (by transaction date) for TPTX within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 11:59pm ET September 17th, 2019
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction Volume or Value Price
Sep 12/19 Sep 10/19 Glaxosmithkline Plc Indirect Ownership Common Stock P - Open market or private purchase 177,777 $45.00
Sep 11/19 Sep 10/19 George Simeon Indirect Ownership Common Stock P - Open market or private purchase 177,777 $45.00
Sep 11/19 Sep 10/19 Larson Yi Direct Ownership Common Stock P - Open market or private purchase 2,222 $45.00
Sep 11/19 Sep 10/19 Countouriotis Athena Direct Ownership Common Stock P - Open market or private purchase 10,000 $45.00
Aug 27/19 Aug 26/19 Larson Yi Direct Ownership Stock Option (right to buy) A - Grant, award or other under Rule 16b-3(d) 312,397  
Jul 25/19 Jul 24/19 Gallagher Carol Giltner Direct Ownership Stock Option (right to buy) A - Grant, award or other under Rule 16b-3(d) 30,000  
May 16/19 May 14/19 Cormorant Asset Management, LP Indirect Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 23,268 $2.19
May 16/19 May 13/19 Cormorant Asset Management, LP Indirect Ownership Stock Options (right to buy) M - Exercise or conversion exempt under rule 16b-3 -23,268  
May 14/19 May 13/19 Machado Patrick Direct Ownership Stock Option (right to buy) A - Grant, award or other under Rule 16b-3(d) 30,000  
Apr 25/19 Apr 25/19 Cormorant Asset Management, LP Indirect Ownership Stock Options (right to buy) Form 3 : Initial Statement of Beneficial Ownership of Securities    
Sign up or login above to see all SEC filings within the past 6 months.
Latest 10 SEC filings (by filing date) for TPTX within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 11:59pm ET September 17th, 2019
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction Volume or Value Price
Sep 12/19 Sep 10/19 Glaxosmithkline Plc Indirect Ownership Common Stock P - Open market or private purchase 177,777 $45.00
Sep 11/19 Sep 10/19 George Simeon Indirect Ownership Common Stock P - Open market or private purchase 177,777 $45.00
Sep 11/19 Sep 10/19 Larson Yi Direct Ownership Common Stock P - Open market or private purchase 2,222 $45.00
Sep 11/19 Sep 10/19 Countouriotis Athena Direct Ownership Common Stock P - Open market or private purchase 10,000 $45.00
Aug 27/19 Aug 26/19 Larson Yi Direct Ownership Stock Option (right to buy) A - Grant, award or other under Rule 16b-3(d) 312,397  
Jul 25/19 Jul 24/19 Gallagher Carol Giltner Direct Ownership Stock Option (right to buy) A - Grant, award or other under Rule 16b-3(d) 30,000  
May 16/19 May 13/19 Cormorant Asset Management, LP Indirect Ownership Stock Options (right to buy) M - Exercise or conversion exempt under rule 16b-3 -23,268  
May 16/19 May 14/19 Cormorant Asset Management, LP Indirect Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 23,268 $2.19
May 14/19 May 13/19 Machado Patrick Direct Ownership Stock Option (right to buy) A - Grant, award or other under Rule 16b-3(d) 30,000  
Apr 25/19 Apr 25/19 Cormorant Asset Management, LP Indirect Ownership Stock Options (right to buy) Form 3 : Initial Statement of Beneficial Ownership of Securities    
Sign up or login above to see all SEC filings within the past 6 months.
Sign up or login above to see the past 6 months of filings sorted by insider. .
Get holdings trends & enhanced insider charts in PDF now
Comment On!
140

Twitter

Search (past week) for $TPTX

StockTwits